The global pharma industry is at a turning point in its transformation. After years of research, the field of advanced cell and gene therapies is achieving new landmarks, and the reality of curative therapies is here. The focus on molecular targets is opening up new possibilities for research, with the innovations which have transformed oncology in recent years making inroads in other diseases. Meanwhile the innovation system which supports new science is also evolving. With much of the advanced science now emerging from fleet-of-foot small pharma and emerging biotech, the power structures of the industry are also in flux. Significant changes will be needed to face the coming innovations in technology, pricing, manufacturing and personalised therapies, all of which present unique challenges to pharma companies' current economic and business models.
Entitled ‘Transforming the Pharma Business for Growth’, the conference will feature an outstanding line-up of speakers sharing their insights, ideas and expertise on topics to include the increasingly complex and uncertain political and pricing environment, manufacturing as the new competitive edge for pharma, and the real-life impacts of AI and advanced technologies in R&D.